Zyversa Therapeutics, Inc. ((ZVSA)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Zyversa Therapeutics, Inc. is conducting a Phase 2a open-label study titled ‘A Phase 2a Open Label Study to Evaluate Cholesterol Efflux Mediator™ VAR200: 2-Hydroxypropyl-β-cyclodextrin (2-HPβCD) in Subjects With Type 2 Diabetic Kidney Disease (DKD).’ The study aims to assess the clinical efficacy and safety of 2-HPβCD in adult patients with type 2 diabetes and diabetic kidney disease (DKD), focusing on its potential to address proteinuria, a common complication of DKD.
Intervention/Treatment: The intervention being tested is 2-Hydroxypropyl-β-cyclodextrin (2-HPβCD), administered intravenously. This drug is designed to remove intracellular cholesterol from the kidney and promote cholesterol efflux, potentially offering a novel treatment approach for DKD.
Study Design: The study is interventional with a single-group assignment. It is open-label, meaning there is no masking, and the primary purpose is treatment. This design allows researchers to observe the direct effects of 2-HPβCD on participants.
Study Timeline: The study began on June 18, 2024, with the latest update submitted on September 17, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its outcomes.
Market Implications: The ongoing study by Zyversa Therapeutics could significantly impact its stock performance and investor sentiment, especially if the results demonstrate positive outcomes. Success in this study could position Zyversa as a leader in DKD treatment, potentially affecting competitors in the diabetic kidney disease treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.